Xtant Medical Holdings Inc ( (XTNT) ) has released its Q4 earnings. Here is a breakdown of the information Xtant Medical Holdings Inc presented to its investors.
Xtant Medical Holdings Inc. is a global medical technology company specializing in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems. The company recently released its financial results for the fourth quarter and full year 2024, showcasing significant revenue growth and strategic advancements.
In 2024, Xtant Medical reported a 28% increase in revenue, reaching $117.3 million, with a notable 12% growth in the fourth quarter alone. Despite a net loss of $16.4 million for the year, the company improved its adjusted EBITDA, reducing losses compared to the previous year. Strategic moves included a new manufacturing and licensing agreement for its SimpliGraft® product and a reduction in operating expenses by over $5 million annually.
Key financial metrics highlighted a gross margin of 58.2% for the year, slightly down from the previous year, attributed to reduced production throughput and inventory write-offs. The company also reported a decrease in fourth-quarter operating expenses due to cost-cutting measures, although full-year expenses rose due to increased sales commissions and R&D investments.
Looking ahead, Xtant Medical has set a revenue guidance of $126 million to $130 million for 2025, anticipating organic growth of 7% to 11%. The company expects to generate free cash flow in the latter half of 2025, supporting its growth without needing additional capital. This outlook reflects management’s confidence in their strategic initiatives and operational efficiencies.
Overall, Xtant Medical’s financial performance in 2024 and its strategic initiatives position it for continued growth in the spinal solutions market, with a focus on enhancing product quality and cost efficiency.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com